Trial Profile

A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 07 Apr 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Agitation; Delirium
Focus Therapeutic Use
Acronyms DahLIA
Sponsors Hospira

Most Recent Events

15 Mar 2016 Primary endpoint has been met. (Ventilator-free hours) as per the results published in the JAMA: the Journal of the American Medical Association
15 Mar 2016 Results published in the JAMA: the Journal of the American Medical Association
18 Jan 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com